Tryon Williams
Vorsitzender bei KIDOZ INC.
Vermögen: 3 Mio $ am 30.06.2024
Aktive Beziehungen
Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
---|---|---|---|---|
Jason Williams | M | 49 | 23 Jahre | |
Eldad Tora | M | 54 | 11 Jahre | |
Henry Bromley | M | 53 | 22 Jahre | |
Fiona Curtis | F | 58 | 15 Jahre | |
Claes Kalborg | M | 62 | 6 Jahre | |
Moshe David | M | 59 | 5 Jahre | |
Lee Groat | M | - |
University of British Columbia
| 21 Jahre |
Neil Cashman | M | 72 |
University of British Columbia
| 19 Jahre |
Yossef Av-Gay | M | 62 |
University of British Columbia
| 30 Jahre |
Michael Hitch | M | - |
University of British Columbia
| 17 Jahre |
Daniel Pauly | M | - |
University of British Columbia
| 30 Jahre |
Kevin McElwee | M | 54 |
University of British Columbia
| 20 Jahre |
R. Scott McKinley | M | 68 |
University of British Columbia
| 23 Jahre |
Steven Plotkin | M | - |
University of British Columbia
| 23 Jahre |
David M. Liu | M | 50 |
University of British Columbia
| 16 Jahre |
Tryon Williams | M | 53 | 5 Jahre |
Beziehungs-Chart
Beziehungen zu mehreren Unternehmen
Ehemalige Beziehungen
Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
---|---|---|---|---|
Nick Glover | M | 55 |
YM BioSciences, Inc.
YM BioSciences, Inc. Pharmaceuticals: MajorHealth Technology YM BioSciences, Inc. operates as a drug development company, which manufactures advancing hematology and cancer-related products. It is currently advancing in late-stage products, which include CYT387, an oral small molecule inhibitor of the kinase enzymes JAK1 and JAK2; and Nimotuzumab, an EGFR targeting humanized monoclonal antibody. The company was founded in 1994 and is headquartered in Mississauga, Canada. | 3 Jahre |
Leonard Vernon | M | 80 |
YM BioSciences, Inc.
YM BioSciences, Inc. Pharmaceuticals: MajorHealth Technology YM BioSciences, Inc. operates as a drug development company, which manufactures advancing hematology and cancer-related products. It is currently advancing in late-stage products, which include CYT387, an oral small molecule inhibitor of the kinase enzymes JAK1 and JAK2; and Nimotuzumab, an EGFR targeting humanized monoclonal antibody. The company was founded in 1994 and is headquartered in Mississauga, Canada. | - |
Ebba Dagmar Lucie Ljungerud | F | 52 | 4 Jahre | |
Helge Seetzen | M | - |
University of British Columbia
| 11 Jahre |
Paul Thomas | M | 50 |
University of British Columbia
| 3 Jahre |
Farzad Forooghian | M | 45 |
University of British Columbia
| 4 Jahre |
Philip Frost | M | 84 |
YM BioSciences, Inc.
YM BioSciences, Inc. Pharmaceuticals: MajorHealth Technology YM BioSciences, Inc. operates as a drug development company, which manufactures advancing hematology and cancer-related products. It is currently advancing in late-stage products, which include CYT387, an oral small molecule inhibitor of the kinase enzymes JAK1 and JAK2; and Nimotuzumab, an EGFR targeting humanized monoclonal antibody. The company was founded in 1994 and is headquartered in Mississauga, Canada. | 5 Jahre |
David Phillips | M | - |
University of British Columbia
| 4 Jahre |
Steve Veitch | M | - |
University of British Columbia
| 5 Jahre |
Ali Kashani | M | 39 |
University of British Columbia
| 3 Jahre |
Derek Hemmes | M | - |
University of British Columbia
| 10 Jahre |
Peeyush Varshney | M | 57 |
University of British Columbia
| 8 Jahre |
Vanessa Collette | F | - |
University of British Columbia
| 5 Jahre |
Johan Petter Erik Nylander | M | 60 | 1 Jahre | |
Akio Tanaka | M | 54 |
University of British Columbia
| 6 Jahre |
Mouane Sengsavang | F | 47 |
University of British Columbia
| 8 Jahre |
James Smith | M | 54 |
YM BioSciences, Inc.
YM BioSciences, Inc. Pharmaceuticals: MajorHealth Technology YM BioSciences, Inc. operates as a drug development company, which manufactures advancing hematology and cancer-related products. It is currently advancing in late-stage products, which include CYT387, an oral small molecule inhibitor of the kinase enzymes JAK1 and JAK2; and Nimotuzumab, an EGFR targeting humanized monoclonal antibody. The company was founded in 1994 and is headquartered in Mississauga, Canada. | 3 Jahre |
Jeff Hunter | M | - |
University of British Columbia
| 6 Jahre |
Li Zhu | F | - |
University of British Columbia
| 3 Jahre |
Wen Chuan Zhou | F | 40 |
University of British Columbia
| 5 Jahre |
Wale Bolorunduro | M | - |
University of British Columbia
| 4 Jahre |
Wen Wei Guan | M | 55 |
University of British Columbia
| 5 Jahre |
Kong Lok Yip | M | 48 |
University of British Columbia
| 5 Jahre |
Michael Leo | M | 47 |
University of British Columbia
| 6 Jahre |
Gabriel Fung | M | - |
University of British Columbia
| 7 Jahre |
Vladimir Cvijetinovic | M | - |
University of British Columbia
| 7 Jahre |
Hon Sum Sam Jor | M | 42 |
University of British Columbia
| 5 Jahre |
Frank S. Moyle | M | - |
University of British Columbia
| 9 Jahre |
Persio Pellegrini Rosario | M | - |
University of British Columbia
| 5 Jahre |
Ben De Wit | M | - |
University of British Columbia
| 7 Jahre |
Dong Xiao Qiu | M | 62 |
University of British Columbia
| 5 Jahre |
Salim Dhanji | M | 44 |
University of British Columbia
| 8 Jahre |
John Priatel | M | 58 |
University of British Columbia
| 11 Jahre |
Nick B. Drake | M | - |
University of British Columbia
| 10 Jahre |
Sebastian Jaimungal | M | - |
University of British Columbia
| 5 Jahre |
Kapil Dhingra | M | 64 |
YM BioSciences, Inc.
YM BioSciences, Inc. Pharmaceuticals: MajorHealth Technology YM BioSciences, Inc. operates as a drug development company, which manufactures advancing hematology and cancer-related products. It is currently advancing in late-stage products, which include CYT387, an oral small molecule inhibitor of the kinase enzymes JAK1 and JAK2; and Nimotuzumab, an EGFR targeting humanized monoclonal antibody. The company was founded in 1994 and is headquartered in Mississauga, Canada. | 1 Jahre |
Catherine Mackey | M | 68 |
YM BioSciences, Inc.
YM BioSciences, Inc. Pharmaceuticals: MajorHealth Technology YM BioSciences, Inc. operates as a drug development company, which manufactures advancing hematology and cancer-related products. It is currently advancing in late-stage products, which include CYT387, an oral small molecule inhibitor of the kinase enzymes JAK1 and JAK2; and Nimotuzumab, an EGFR targeting humanized monoclonal antibody. The company was founded in 1994 and is headquartered in Mississauga, Canada. | 2 Jahre |
George Whitton | M | 86 | - | |
Amanda Gale Miller | F | 42 |
University of British Columbia
| 8 Jahre |
Jacqueline Simpson | F | - |
University of British Columbia
| 11 Jahre |
Robert E. Cohen | M | - |
University of British Columbia
| 11 Jahre |
Thomas Ian Alexander Allen | M | 83 |
YM BioSciences, Inc.
YM BioSciences, Inc. Pharmaceuticals: MajorHealth Technology YM BioSciences, Inc. operates as a drug development company, which manufactures advancing hematology and cancer-related products. It is currently advancing in late-stage products, which include CYT387, an oral small molecule inhibitor of the kinase enzymes JAK1 and JAK2; and Nimotuzumab, an EGFR targeting humanized monoclonal antibody. The company was founded in 1994 and is headquartered in Mississauga, Canada. | - |
Roger Quick | M | - |
University of British Columbia
| 7 Jahre |
Henry Friesen | M | 90 |
YM BioSciences, Inc.
YM BioSciences, Inc. Pharmaceuticals: MajorHealth Technology YM BioSciences, Inc. operates as a drug development company, which manufactures advancing hematology and cancer-related products. It is currently advancing in late-stage products, which include CYT387, an oral small molecule inhibitor of the kinase enzymes JAK1 and JAK2; and Nimotuzumab, an EGFR targeting humanized monoclonal antibody. The company was founded in 1994 and is headquartered in Mississauga, Canada. | - |
Hans Knapp | M | - |
University of British Columbia
| 3 Jahre |
Arsalan Farrokh | M | - |
University of British Columbia
| 4 Jahre |
Claire Huxtable | F | - |
University of British Columbia
| 6 Jahre |
Shaun Foy | M | - |
University of British Columbia
| 9 Jahre |
François Thomas | M | 66 |
YM BioSciences, Inc.
YM BioSciences, Inc. Pharmaceuticals: MajorHealth Technology YM BioSciences, Inc. operates as a drug development company, which manufactures advancing hematology and cancer-related products. It is currently advancing in late-stage products, which include CYT387, an oral small molecule inhibitor of the kinase enzymes JAK1 and JAK2; and Nimotuzumab, an EGFR targeting humanized monoclonal antibody. The company was founded in 1994 and is headquartered in Mississauga, Canada. | 5 Jahre |
Trevor Robinson | M | - |
University of British Columbia
| 18 Jahre |
Christopher Mark Devereux | M | 59 | 16 Jahre | |
Mark Kowalski | M | 69 |
YM BioSciences, Inc.
YM BioSciences, Inc. Pharmaceuticals: MajorHealth Technology YM BioSciences, Inc. operates as a drug development company, which manufactures advancing hematology and cancer-related products. It is currently advancing in late-stage products, which include CYT387, an oral small molecule inhibitor of the kinase enzymes JAK1 and JAK2; and Nimotuzumab, an EGFR targeting humanized monoclonal antibody. The company was founded in 1994 and is headquartered in Mississauga, Canada. | - |
Matthew Hamilton | M | 41 |
University of British Columbia
| 5 Jahre |
Arie Page | F | 45 |
University of British Columbia
| 8 Jahre |
Jonathan Bey | M | 54 |
University of British Columbia
| 5 Jahre |
Lei Huang | F | 41 |
University of British Columbia
| 4 Jahre |
Leonardo Viana Nicacio | M | - |
YM BioSciences, Inc.
YM BioSciences, Inc. Pharmaceuticals: MajorHealth Technology YM BioSciences, Inc. operates as a drug development company, which manufactures advancing hematology and cancer-related products. It is currently advancing in late-stage products, which include CYT387, an oral small molecule inhibitor of the kinase enzymes JAK1 and JAK2; and Nimotuzumab, an EGFR targeting humanized monoclonal antibody. The company was founded in 1994 and is headquartered in Mississauga, Canada. | 2 Jahre |
Michael Minor | M | - |
University of British Columbia
| 4 Jahre |
Jim Chan | M | - |
University of British Columbia
| 4 Jahre |
Asha Reeves | F | 52 |
University of British Columbia
| 4 Jahre |
Kristina Hess | F | - |
University of British Columbia
| 4 Jahre |
Rajeena Minhas | F | - |
University of British Columbia
| 4 Jahre |
Wendi V. Rodrigueza | M | 58 |
University of British Columbia
| 3 Jahre |
Adrian Crawford Ansell | M | 65 |
University of British Columbia
| 5 Jahre |
John Edward Veltheer | M | 58 |
University of British Columbia
| 3 Jahre |
Nousheen Huq | F | 53 |
University of British Columbia
| 3 Jahre |
Glans Graydon | M | 37 |
University of British Columbia
| 4 Jahre |
Keith Gillard | M | - |
University of British Columbia
| 5 Jahre |
Ryan Weymark | M | - |
University of British Columbia
| 4 Jahre |
Yao Yao | M | 35 |
University of British Columbia
| 4 Jahre |
Rory Edward North | M | - |
University of British Columbia
| 4 Jahre |
Ross Smith | M | 85 |
University of British Columbia
| 6 Jahre |
Brad Peters | M | 51 |
University of British Columbia
| 4 Jahre |
Michael Shaw | M | - |
University of British Columbia
| 4 Jahre |
Alvin Cheung | M | - |
University of British Columbia
| 5 Jahre |
Michael Leung | M | - |
University of British Columbia
| 4 Jahre |
Colin I. Godwin | M | 84 |
University of British Columbia
| 24 Jahre |
Chadwick Wasilenkoff | M | - |
University of British Columbia
| 4 Jahre |
Kevin Cohen | M | - |
University of British Columbia
| 3 Jahre |
Abdul Farooqi | M | - |
University of British Columbia
| 4 Jahre |
Wendy Louise Bach | F | 69 |
University of British Columbia
| 3 Jahre |
Randy Smallwood | M | 59 |
University of British Columbia
| 4 Jahre |
Jason Ng | M | - |
University of British Columbia
| 4 Jahre |
Paul McMillan | M | - |
University of British Columbia
| 4 Jahre |
Statistik
Land | Beziehungen | % des Gesamten |
---|---|---|
Kanada | 89 | 89,00% |
Vereinigtes Königreich | 11 | 11,00% |
Alter der Beziehungen
Aktive
Vergangene
Herr
Frau
Aufsichtsräte
Führungskräfte
Ursprung der Beziehungen
- Börse
- Insiders
- Tryon Williams
- Persönliches Netzwerk